Rybodyn
RyboDyn is a pioneering immunotherapy developer focused on unlocking the dark proteome using proprietary RyboCypher™ technology. They aim to transform hidden biological signals into breakthrough therapies, redefining patient care through next-generation immunotherapies. Their mission is to turn the secrets of the dark genome into actionable insights and first-in-class immunotherapies that revolutionize healthcare.
Industries
Nr. of Employees
small (1-50)
Products
Sequencing and AI proteogenomic discovery platform
Integrated platform that combines high-resolution RNA sequencing with machine learning models and curated proteomic datasets to detect cryptic RNAs and predict encoded proteins for target discovery.
Antibody-based immunotherapy candidates
Preclinical antibody drug candidates derived from discovered disease-specific targets designed for high specificity and reduced off-target effects, intended for advancement toward clinical development.
Sequencing and AI proteogenomic discovery platform
Integrated platform that combines high-resolution RNA sequencing with machine learning models and curated proteomic datasets to detect cryptic RNAs and predict encoded proteins for target discovery.
Antibody-based immunotherapy candidates
Preclinical antibody drug candidates derived from discovered disease-specific targets designed for high specificity and reduced off-target effects, intended for advancement toward clinical development.
Services
Discovery and experimental validation of disease-specific peptide and cell-surface targets derived from non-canonical transcripts, leveraging sequencing, proteomics, and clinical repository correlation.
Partnership-driven projects that integrate discovery outputs with clinical tumor banks and metadata to accelerate translation of targets into therapeutic programs.
Discovery and experimental validation of disease-specific peptide and cell-surface targets derived from non-canonical transcripts, leveraging sequencing, proteomics, and clinical repository correlation.
Partnership-driven projects that integrate discovery outputs with clinical tumor banks and metadata to accelerate translation of targets into therapeutic programs.
Expertise Areas
- Dark proteome and dark transcriptome discovery
- Proteogenomics
- AI-driven target identification
- Antibody-based immunotherapy development
Key Technologies
- High-resolution RNA sequencing
- Proteogenomic machine learning models
- Proprietary transcriptomic and proteomic databases
- Proteomic discovery workflows (peptide detection)
News & Updates
RyboDyn's collaboration with Lilly aims to advance dark proteome targets into first-in-class therapies.
RyboDyn has expanded its collaboration with Moffitt Cancer Center to validate and develop dark targets for cancer immunotherapy.
RyboDyn announced the discovery of a cryptic human proteome and secured $4 million in pre-seed funding.
RyboDyn's collaboration with Lilly aims to advance dark proteome targets into first-in-class therapies.
RyboDyn has expanded its collaboration with Moffitt Cancer Center to validate and develop dark targets for cancer immunotherapy.
RyboDyn announced the discovery of a cryptic human proteome and secured $4 million in pre-seed funding.